Atea Pharmaceuticals, Inc.(AVIR)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Atea Pharmaceuticals, Inc. (AVIR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. AVIR is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of AVIR by reported 13-F value include FMR, BlackRock, BML Capital Management, based on the most recent SEC filings. AVIR trades on the Nasdaq exchange and files with the SEC under CIK 1593899. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVIR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Atea Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

$-32.9M

AVIR key financials by period

Atea Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202110-K$351.4M$121.2M39.4%
FY 202010-K$48.6M$-10.9M-22.7%

Institutions holding AVIR

Institutional investors reporting a position in Atea Pharmaceuticals, Inc. on SEC Form 13F.
InstitutionSharesValueReported
FMR12,004,064$55.8M2026-06-30
BlackRock8,720,077$40.5M2026-06-30
BML Capital Management6,952,330$32.3M2026-06-30
TANG CAPITAL MANAGEMENT4,814,700$22.4M2026-06-30
VANGUARD CAPITAL MANAGEMENT2,964,862$13.8M2026-06-30
Bain Capital Life Sciences Investors2,075,639$9.7M2026-06-30
ACADIAN ASSET MANAGEMENT2,035,192$9.5M2026-06-30
GEODE CAPITAL MANAGEMENT1,958,435$9.1M2026-06-30
STATE STREET1,652,399$7.7M2026-06-30
TWO SIGMA INVESTMENTS1,506,697$7.0M2026-06-30
SEC EDGAR: CIK 1593899 →
AVIR

Atea Pharmaceuticals, Inc.

AVIR
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-32.93M

EPS (Diluted)

Q2 2026
EDGAR

$-0.41

ROIC

Q2 2026
EDGAR

-68.8%

Top Institutional Holders

as of Q2 2026
$276.51M total
FMR LLC
$55.82M+0.4%
BlackRock, Inc.
$40.55M+3.4%
BML Capital Management, LLC
$32.33M-1.5%
TANG CAPITAL MANAGEMENT LLC
$22.39M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$13.79M-8.7%
Bain Capital Life Sciences Investors, LLC
$9.65M-12.1%
ACADIAN ASSET MANAGEMENT LLC
$9.46M+28.6%
GEODE CAPITAL MANAGEMENT, LLC
$9.11M+12.1%
STATE STREET CORP
$7.68M-2.5%
TWO SIGMA INVESTMENTS, LP
$7.01M-19.2%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…